Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

Background: Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dementia. The recent advent of blood-based markers opens the door for more accessible...

Full description

Bibliographic Details
Main Authors: Bali, D. (Author), Blennow, K. (Author), Buckley, C.J (Author), Farrar, G. (Author), Hansson, O. (Author), Janelidze, S. (Author), Palmqvist, S. (Author), Pichet Binette, A. (Author), Wolk, D.A (Author), Zetterberg, H. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
aged
Alzheimer disease
Alzheimer Disease
Alzheimer’s disease
amnesia
amyloid beta protein
amyloid beta protein[1-40]
amyloid beta protein[1-42]
Amyloid beta-Peptides
Article
brain size
cognition
cognitive defect
Cognitive Dysfunction
Dementia
disease exacerbation
Disease Progression
female
genetics
genotype
glial fibrillary acidic protein
human
Humans
major clinical study
male
metabolism
Mild cognitive impairment
neurofilament protein
Plasma biomarkers
prediction
protein phosphorylation
psychology
p-tau
scoring system
tau protein
tau Proteins
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items